Glooko conducted the study to examine remote patient monitoring uptake and diabetes-related outcomes during the COVID-19 pandemic for people with diabetes using a remote care solution.
Glooko conducted the study to determine if a comprehensive RPM diabetes management program was more effective in reducing HbA1c compared to usual care.
Glooko conducted this HEOR study to estimate the impact of remote patient monitoring and digital therapeutics technology on diabetes outcomes, healthcare resource use and costs.
Using secondary analyses to examine whether the comprehensive Glooko remote patient monitoring diabetes management program improved diabetes-related distress compared to usual care in a sample of adults with type 2 diabetes.
Glooko’s novel algorithm to assess glycemic control performs well compared to clinician assessment and helps clinicians make treatment decisions faster.
In the study funded by Glooko, mobile-enabled remote patient monitoring (RPM) with weekly monitoring and episodic telephonic coaching led to significantly improved A1C after 24 weeks.